MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
marketable securities
$6,000K
Proceeds from exercise of
share options
$656K
Net cash provided by
investing activities
$4,219K
Net cash provided by
financing activities
$656K
Total revenue
$106,677K
Canceled cashflow
$1,781K
(decrease) increase in cash
and cash...
-$8,900K
Canceled cashflow
$4,875K
Net income
$12,971K
Share-based compensation
expense
$6,302K
Increase in accounts
payable
$5,974K
Depreciation
$948K
Non-cash lease expense
$627K
Other
-$534K
Decrease (increase) in
other operating...
-$150K
Canceled cashflow
$93,706K
Purchase of property and
equipment
$1,781K
Net cash (used in)
provided by operating...
-$13,775K
Canceled cashflow
$27,506K
R&d
expenses-External RD
$38,792K
Sg&a expenses-Other
Selling General And...
$21,065K
R&d
expenses-Salaries And Other...
$14,140K
Sg&a
expenses-Salaries And Other...
$13,090K
Other segment
(expense) income, net
$6,185K
Cost of revenue from
sale of therapies
$434K
Increase in prepayments
and other current...
$18,772K
Decrease in accrued
expenses
-$8,303K
(increase) decrease in
accounts receivable
$7,930K
Unrealized foreign
exchange gains, net
$3,490K
Unrealized gains on
marketable securities
$1,776K
(decrease) increase in
operating lease...
-$864K
Decrease in deferred
revenue
-$146K
PRAMEPrograms
$21,214K
Other Clinical And Pre
Clinical Costs
$8,493K
Tebentafusp Programs
$8,239K
Infectious Disease
Programs
$846K
Back
Back
Cash Flow
source: myfinsight.com